Leo Brokerage LLC Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Leo Brokerage LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 300,760 shares of the company’s stock, valued at approximately $53,303,000. Johnson & Johnson accounts for approximately 8.5% of Leo Brokerage LLC’s holdings, making the stock its biggest holding.

Several other institutional investors also recently bought and sold shares of JNJ. Norges Bank purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. grew its holdings in Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares during the last quarter. GQG Partners LLC grew its holdings in Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after purchasing an additional 3,627,424 shares during the last quarter. State Street Corp grew its holdings in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after purchasing an additional 1,084,834 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

NYSE JNJ opened at $174.52 on Monday. The company has a market capitalization of $459.23 billion, a PE ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a fifty day moving average of $175.95 and a 200 day moving average of $174.46. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.48 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Citigroup dropped their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Raymond James boosted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.